Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

BACKGROUND: This is the first trial to directly compare efficacy and safety of alectinib versus standard chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients who have progressed on, or were intolerant to, crizotinib. PATIENTS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Novello, S, Mazières, J, Oh, I -J, de Castro, J, Migliorino, M R, Helland, Å, Dziadziuszko, R, Griesinger, F, Kotb, A, Zeaiter, A, Cardona, A, Balas, B, Johannsdottir, H K, Das-Gupta, A, Wolf, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005013/
https://www.ncbi.nlm.nih.gov/pubmed/29668860
http://dx.doi.org/10.1093/annonc/mdy121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005013/
https://www.ncbi.nlm.nih.gov/pubmed/29668860
http://dx.doi.org/10.1093/annonc/mdy121

Ejemplares similares